Attitudes of Psychiatrists Toward Antipsychotic Depot Medication

Article Abstract Background: Since 2002, a second-generation depot antipsychotic has been available that potentially combines the advantages of depot administration and the favorable aspects of the so-called "atypical" antipsychotics. Nevertheless, long-acting injectable formulations are seldom prescribed in the treatment of schizophrenia. Method: We surveyed 350 psychiatrists at an international conference as to their reasons for not...